Search

Displaying results 1051 - 1060 of 6076 in total
  1. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L41290] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended lutetium Lu-177 vipivotide tetraxetan be granted marketing authorization for the treatment of prostate … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

  2. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A241045] In December 2022, ublituximab was approved by the US FDA for the treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody for multiple sclerosis … allowing for administration in a one-hour infusion twice-a-year following the starting dose.

  4. Drug

    Fluocortolone

    go.drugbank.com/drugs/DB08971
    ApprovedWithdrawn

    Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Corticosteroids for Systemic Use, Plain
  5. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  6. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [A187838] Standard therapy for anemia in patients with MDS involves the use of erythropoiesis-stimulating agents (e.g. … [A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888]

  7. Drug

    Sulfanilamide

    go.drugbank.com/drugs/DB00259
    ApprovedWithdrawn

    Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    [L6535] Brimonidine is the first topical treatment approved for facial erythema of rosacea.[A178978] … [A178945] Thus brimonidine is an effective and safe alternative to beta-blockers, in patients with, or at high risk for, cardiopulmonary disease.

  9. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).

  10. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized